Unresectable intrahepatic cholangiocarcinoma (iCCA) remains brutal. Gem/Cis alone → ~3% 3-year OS. 💥 PUMP-2 (JCO 2025) adds HAIP FUDR + Gem/Cis → 📈 Median OS 22.3 mo 💪 1-yr OS 80% 🔥 3-yr OS 31.5% Not randomized, but striking signal. Pump trials aren’t easy; select

In RAPIDO, higher LRR w short course TNT confined to pts undergoing sphincter-preserving surg (12 v 5%), w distal resection margin <1cm as predictor. Suggests need to re-eval safe margin & consider basing surg off original tumor extent. Caveat: post hoc, exploratory analysis.

Quality metrics for breast and regional nodal RT - practical tips https://t.co/puwy8SPhi5 via @YouTube @ARRO_org @ACROresident @AndrewKellerMD @ErinGillespieMD @ColinChampMD @KamravaMD

Protocol Activation! Effective October 07, 2025, NRG-GI012 is open to patient entry. NRG-GI012: Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with Macrovascular Invasion (HELIO-RT) @MGHCancerCenter https://t.co/CuJc83UqSF

On Monday, Sept 29th, we announced the activation of NRG-GY037, a pivotal Phase III randomized trial for patients with high-risk, locally advanced cervical cancer. PI: Jyoti Mayadev, MD @UCSDHealth Read more: https://t.co/cZoM4WZsL3

💥 It’s here! The new ESMO Clinical Practice Guidelines for localized rectal cancer (@Annals_Oncology) 🔗 https://t.co/0AkhwH6c9D 📌 Covers: •Imaging & diagnosis •Staging & risk assessment •Treatment & follow-up •Algorithms for local & LA disease When it comes to rectal

At #ASTRO25, Nancy Lee, MD, (@imrtlee @MSKCancerCenter) shares findings of the KEYNOTE-689 study, the addition of neoadjuvant and adjuvant (starting concurrently with postoperative radiotherapy [PORT] ± cisplatin) pembro to SOC significantly improved event-free survival (EFS) vs

#ASTRO25 ASTRO ROI 5k @RO_Institute Where is @TylerSbrt Run 🏃 by 💦

Starting the morning with @MikeChuongMD reviewing multi-center series of definitive dose-escalated XRT for resectable #PDAC which showed reasonable outcomes w/ low toxicity (<5% acute, <10% late) for operable pts who decline surgery. #ASTRO25

#ASTRO25 @UCSDRadMed Alumni Night

SBRT vs IMRT for #ProstateCancer PACE-B: high SBRT dose ➡️ slightly higher tox. Great onc outcomes GU005: low SBRT dose ➡️ slightly lower tox. Slightly worse BCR RadTARGET: asking a good Q! Focal boost w de-intensification of normal prostate. NCT06990542 #ASTRO25 @UCSDCancer

#ASTRO25 METIS TTF + SRS improved time to distant intracranial progression HR 0.72 @Novocure

#ASTRO25 NRG GU005 SBRT vs hypofractionated radiation for intermediate risk prostate cancer @NRGonc Improved Rectal tox, Sexual fxn, and Urinary incontinence with SBRT Slightly worse BCF with SBRT Maybe need 40Gy/5 or Flame boost instead of 36.25/5

#ASTRO25 Kuma Sushi Uni from Hokkaido, Hamachi Ponzu, and Chawanmushi🔥🔥🔥

Great talk @MikeChuongMD with practical tips for Panc ablative RT. With superior soft-tissue contrast MRgRT, you're able to really drive high doses at the OAR/tumor interface. Wonder how successful that is with CTgRT, as it may ultimately impact disease progression. #ASTRO25

#ASTRO25 GBM biology driven, adaptive and innovative RT experimental frontiers Looking forward to enroll on NRG pulsed low-dose rate RT for potential improved tumor control with less toxicity @NRGonc

Yes very good … imo still have to say Russ and Daughters wins but close second. Btw Off Center in Reno pretty good!

#ASTRO25 SF takes on NYC for Best Bagel

#ASTRO25 Sunday Night dinner at Spruce SF out with the whole renown rad onc team